Advertisement

Search Results

Advertisement



Article Topics

Your search for Alice Goodman matches 10 pages

Showing 1 - 10


breast cancer

SABCS 2014: Oncotype DX DCIS Score Reliably Predicts Breast Cancer Recurrence in Patients With DCIS

Ductal carcinoma in situ (DCIS), which accounts for 30% of all newly diagnosed breast cancer, is actually a precancerous lesion. A proportion of patients will have progression to invasive breast cancer, but up until recently, it has not been possible to identify which patients require further...

breast cancer

SABCS 2014: Ovarian Suppression Added to Hormonal Therapy Reduces Risk of Recurrence in Some Premenopausal Women

Results of the large international SOFT trial present a convincing argument for the addition of ovarian function suppression to adjuvant hormonal therapy to reduce the risk of recurrence in premenopausal women with hormone receptor–positive breast cancer at high enough risk to be treated with ...

breast cancer

SABCS 2014: PI3K Inhibition With Pictilisib in Hormone Receptor–Positive Breast Cancer Not Ready for Prime Time

Interest is high in studying the PI3K pathway in hormone receptor–positive breast cancer, but it is not clear which of the PI3K inhibitors under development—if any—will be a “home run.” Adding the pan-class I selective PI3K inhibitor pictilisib to fulvestrant...

breast cancer

Palbociclib Plus Letrozole Achieves Impressive Results in Metastatic Breast Cancer

First-line treatment with the combination of palbociclib plus letrozole extended progression-free survival by approximately 50% in patients with metastatic estrogen receptor–positive, HER2-negative breast cancer, according to final results of a randomized phase II study presented at the...

breast cancer

Adjuvant Bisphosphonates Improve Breast Cancer Survival, Reduce Bone Recurrence in Postmenopausal Women With Early Disease

Adjuvant use of bisphosphonates reduced the risk of bone recurrence by 34% and the risk of breast cancer death by 17% in postmenopausal women with early breast cancer in a large meta-analysis conducted by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). The potentially...

breast cancer

Anastrozole Reduces Primary Breast Cancer Incidence by More Than 50% in High-Risk Postmenopausal Women

Five years of treatment with anastrozole reduced the risk of primary breast cancer by 53% in postmenopausal women at high risk for developing the disease, according to an analysis of the IBIS II trial. Anastrozole reduced the risk of estrogen receptor–positive invasive cancers by 58%. The...

breast cancer

Less Is More: Postoperative Radiation May Be Avoided in Older Women With Estrogen Receptor–Rich Tumors

Among older women with hormone receptor–positive breast cancer, it is reasonable to omit whole-breast radiation therapy after breast-conserving surgery and neoadjuvant hormone therapy if the patient’s tumors have high levels of estrogen receptor expression, but radiation should remain...

breast cancer

Addition of Bevacizumab Fails to Improve Invasive Disease-Free Survival vs Adjuvant Chemotherapy/Trastuzumab Alone in HER2-Positive Breast Cancer

Bevacizumab (Avastin) failed to extend invasive disease–free survival when added to trastuzumab (Herceptin)-directed adjuvant chemotherapy in patients with HER2-positive breast cancer in the phase III BETH trial. Although not specifically designed to answer this question, BETH also...

breast cancer

ECC 2013: Strong Showing for Ado-Trastuzumab Emtansine in Heavily Pretreated Advanced HER2-Positive Breast Cancer

Results of the phase III TH3RESA trial show that the antibody-conjugate ado-trastuzumab (Kadcyla, previously known as T-DM1) extends progression-free survival in women with advanced HER2-positive breast cancer that progressed on two or more previous HER2-directed therapies including trastuzumab...

breast cancer

ECC 2013: Radiation to Chest Lymph Nodes Improves Survival in Early Breast Cancer

Extending radiation to the lymph nodes behind the sternal wall and above the collarbone extends overall survival in patients with stage I to III breast cancer and does not increase toxicity compared to conventional locoregional radiation therapy, according to 10-year results of an international...

Advertisement

Advertisement



;
Advertisement